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Little is known about the cancer related fatigue (CRF) along cancer course and risk factors that could
predict CRF development and persistence in breast cancer (BC) survivors.
This prospective study detected incidence, timing of onset, duration of CRF, impact on QoL and psy-
chological distress.
Seventy-eight early BC patients, undergoing chemotherapy (CT) followed or not by hormonal therapy
were assessed for QoL and psychological distress by EORTC QLQC30 and HADs questionnaires. Fatigue
was investigated with mix methods, structured interview and psychometric measures. A qualitative
analysis was added to assess the behavioral pattern of CRF.
Low fatigue levels were identified after surgery (9%), increasing during (49%) and at the end of CT
(47%), maintaining after 1 year (31%) and declining up to ten years of follow-up. Prevalence of CRF was
higher at the end of CT and lower at follow-up. At the end and after 1 and 2 years from CT, persistence of
CRF was associated to anxiety in 20%, 11% and 5% and to depression in 15%, 10% and 5% respectively. A
relationship between CRF and psychological distress was observed; patients presenting depression and
anxiety before CT were at higher risk for fatigue onset at a later period. A relationship between fatigue
and QoL was noted at the end of CT.
Our study shows the fatigue timely trend in early BC patients from surgery, CT and follow-up. Iden-
tification of biological, psychological, social predictor factors related to fatigue could be helpful for early
interventions in patients at higher risk of developing fatigue.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The increasing effectiveness of adjuvant therapies has resulted
in an ever-increasing number of cancer survivors. However, many
survivors experience long-term adverse effects due to previous
treatments which deteriorate health-related quality of life (HRQOL)
[1e3].
One of the most frequent adverse effects reported in cancer
patients undergoing systemic treatments is fatigue.
Fatigue is a condition that involves a subjective sense of weak-
ness, lack of energy and/or tiredness. The etiology of cancer-relatedogy 1, Regina Elena National
).
Ltd. This is an open access article ufatigue (CRF) has not yet been thoroughly elucidated, although it
may involve several physiological, biochemical, and psychological
systems which in turn might vary according to kind of tumor, stage
of disease, and treatment [4].
In the analysis carried out on BC patients undergoing treatment
and in the first 5 years after completing treatment, it was shown
that depression was one of the strongest factors related to CRF
[5e7]. Despite the recent rise in research interest in this area, the
nature and direction explaining these variables remain uncertain.
Other studies suggest that CRF and depression are independent
conditions in cancer patients with differing patterns over the
course of disease and with different underlying mechanisms [8,9].
These conflicting results could also be related to the measurements
utilized and to their ability in distinguishing CRF from depression
[10e13]. There is a need for validated instruments able to accu-
rately assess CRF and distinguish CRF from depression. A clearnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tween CRF and depression may define a better prevention and care
strategy.
In addition, anxiety is consistently associated with CRF despite
that this psychological variable has not been extensively explored
[2,14].
Other aspects include the relationship between CRF, disease,
treatment-related factors, socio-demographic variables, age at
early BC diagnosis and pre-treatment CRF score. Conflicting factors
were reported in this field [1,5,15e23].
The CRF is one of the most notable symptoms associated with
cancer and its treatments. It is reported to be the single most dis-
tressing symptom with the greatest negative impact on HRQoL
[1e3,24e25]. Lower HRQoL and its negative effects on daily func-
tioning have been reported in patients undergoing chemotherapy
as well as in some BC survivors after chemotherapy [26,27].
CRF may lead to poor compliance with chemotherapy (CT)
regimens [28,29] and is often the reason for patients discontinuing
the treatment [30].
There is notmuch data regarding the long-term trajectory of CRF
or the relationship with HRQoL and psychological distress.
Previous findings reported that CRF is typically resolved in the
year after completing treatment but, to date, approximately 30% of
patients experience more persistent CRF that may endure for up to
10 years ormore [22].When CRF persists for 6months or longer it is
chronic fatigue (CF), which is of special relevance in cancer survi-
vors [21,31] but to date not yet prospectively studied.
Previous studies on BC patients treated with systemic therapies
showed rates of CRF ranging between 35% and 40% at 2 and 3 years
after therapy, respectively compared with 11% in those without a
history of cancer [32,33]. The latest findings have reported a CRF
incidence rate of about 10%e24% before adjuvant CT and 26%e31%
at the end of these treatments [17,34]. Reports from prospective
studies after adjuvant therapies span from a prevalence of 39% and
23% at 2 and 4 years, respectively [7], to 34% and 21% at 3.5 and 6.5
years, respectively [22]. Up to now there has been no recent pro-
spective results that have verified the permanence of CRF after 5
years from diagnosis of early BC with drugs used in the adjuvant
setting, both as chemotherapy and aromatase inhibitors or
tamoxifen. So, it is very important to study the fatigue phenomena
in the course of 10 years after systemic treatment especially in light
of the increase of survival of women affected by breast cancer and
the impact that CRF could have on quality of life.
Here, we report findings of a mono-institutional prospective
study on CRF in patients with diagnosed BC and treated with CT
followed or not by hormonal therapy (HT).
In this study we carefully explored the time course and the
behavior over 10 years of CRF and psychological distress; the time
course of HRQoL and the relationship between CRF and HRQol,
psychological distress and clinical features in early BC patients
undergoing CT ± HT.
The CRF will be investigate with mix methods, structured
interview and psychometric measures.
2. Material and methods
Patients with newly diagnosed early BC and who were eligible
for adjuvant CT followed or not by HT were included and assessed
after surgery for primary tumors. The patients were followed pro-
spectively and were participated in a long-term follow-up study.
Exclusion criteria included patients with ipsilateral breast and/
or axillary recurrences and/or a previous contralateral BC. More-
over, patients with psychiatric illness, unable to fill in question-
naires, with concurrent chronic/life threatening disease where
fatigue was a prominent symptom were not eligible.The study was approved by the Ethics Committee of Regina
Elena National Cancer Institute in Rome (Italy). Informed consent
was signed by the patients at study entry.
Assessment. Patients were assessed by an oncologist throughout
the period of treatment and by a psychologist once week before
starting CT, after 3 or 4 cycles and 1 month after 6 or 8 cycles of CT;
after the end of CT all patients were assessed by an oncologist and a
psychologist at 6, 12 months and then annually for the following 10
years from the start of CT. The follow up by oncologist was carried
out in accordance with the international guidelines (American
Society of Clinical Oncology).
For the results, we defined the assessment of patients in relation
to the time of CT and to the follow up in which patients were
submitted or not to HT (from the end of CT to a total of 5 years): T0
(oneweek before the start of CT), T1 (after 3 or 4 cycles of CT), T2 (at
the end of CT and at the start of HT for those patients with positive
hormonal receptors) T3 (after 1 year to the end of CT, and with or
without HT), T4 (after 2 years to CT), T5 (after 5 years to CT), T6
(after 10 years to CT).
Adjuvant treatments. Adjuvant CT included regimens with three
weekly anthracyclines followed or not by taxanes or not including
anthracycline regimens (such as Cyclophosphamide, Methotrexate,
Fluorouracil [CMF]). Adjuvant HT consisted of tamoxifen or aro-
matase inhibitors in premenopausal or in postmenopausal patients,
respectively. After CT patients underwent complementary radio-
therapy in case of conservative surgery and/or metastases in axil-
lary lymphonodes (4).
Toxicity assessment. Toxicity was assessed before each drug
administration, via physical examination, hematology and
biochemistry exams. Adverse events were graded in accordance
with the National Cancer Institute (NCI) common toxicity criteria
(NCICT-CAE) version 4.0 [35].
CRF and Psychological measurement. In order to perform psy-
chological assessment, a battery of questionnaires aimed to assess
the quality of life (EORTC QLQ C30 and QLQ BR23 for BC module),
psychological distress (HADs) and CRF (FACT-F) were administered.
The EORTC QLQ-C30 questionnaire (version 0.3) explores the
following functional areas: physical, role, emotional, cognitive, and
social as well as global quality of life index. It also includes a
number of multi-item scales and single items that assess a range of
physical symptoms (CRF, nausea and vomiting, pain, dyspnea, sleep
disturbance, loss of appetite, constipation, and diarrhoea) as well as
financial difficulties [36].
The EORTC scores range from 0 to 100. Higher scores represent a
better level of QoL in the functional areas, but a higher degree of
symptoms [37].
The course of distress was investigated with the HAD scale
which is a reliable and valid instrument for assessing anxiety and
depression in patients. Hospital Anxiety and Depression scale
(HADS) [38] is a 14 item questionnaire consisting of two subscales,
anxiety and depression. Each item is rated on a four point scale
from 0 to 3 giving a maximum score of 21 on each subscale. Ac-
cording to Carroll et al. [39] scores from 0 to 7 indicate normal
levels, scores between 8 and 10 on Anxiety and Depression sub-
scales indicate borderline cases, while scores¼> 11 identify clinical
cases. The cut-off scores of 14 and 19 on the HAD-S Total were used
to evaluate likely psychiatric caseness and caseness. respectively.
The advantage of using the HADS is that its depression subscale
does not include any physical symptoms such as lack of energy or
sleep disturbance, thereby reducing potential contamination of the
relationship with a measure of CRF. In this study, psychological
distress has been assessed with a mean score and severity
threshold.
In addition the persistence of psychological distress was
assessed on the basis of the number of patients showing levels 8
Table 1
Patient's characsteristics.a
N (%)
Total patients enrolled 112
Patients evaluable for the study 78 (69.6)
Age (years) (median and range) 49 (26e74)
Menopausal Status
Pre 41 (52.5)
Post 37 (47.5)
Hormonal Receptor
Positive 43 (55)
Negative 35 (45)
Type of Surgery
Quadrantectomy 54 (69)
Mastectomy 24 (31)
Stage of disease
I 39 (49)
II 26 (34)
III 13 (17)
Adjuvant Chemotherapy plus Hormonal Therapy 43 (55)
Adjuvant Chemotherapy alone 35 (45)
Chemotherapy
Anthracycline alone 25 (32)
Anthracycline/Taxanes 39 (50)
Not including anthracycline/taxanes 14 (18)
Hormonal Therapy
Tamoxifenb 26 (33)
Aromatase Inhibitor 17 (22)
Radiotherapy on the breast ± axilla 65 (58)
Basal value of haemoglobin (gr/dl) (median and range) 12 (8.5e15.2)
Global QoL (mean ± standard deviation) 72.31 ± 13.26
Anxiety (mean ± standard deviation) 7.99 ± 2.47
Depression (mean ± standard deviation) 7.81 ± 2.81
CRF (mean ± standard deviation) 45.13 ± 6.14
a Among 112 patients enrolled in the study, 34 of them did not meet the inclusion
criteria.
b Tamoxifen ± LHRH analogue.
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follow-up (T6).
The FACT-F and -Anemia scales, in particular, have shown strong
associations with hemoglobin level, functional status, and global
QOL [40e44].
The Functional Assessment of Cancer Therapy-Fatigue (FACT-F)
subscale is a 13-item questionnaire that is part of the 20-item
anemia module (FACT-An) of the FACIT quality of life assessment
system. The FACT-F has well-validated psychometric properties
[40] and has been used in a large number of intervention studies to
treat CRF [45]. Scores can range between 0 and 52with lower scores
indicating greater CRF [46]. For this study, italian validated version
of FACT-F was used.
Some authors detected a cut-off of 36 as the optimal score to
identify patients with and without significant CRF [15]. The persis-
tence of CRF was assessed based on the number of patients who
showed levels of fatigue<36 continuously fromT1, time of CRFonset,
and up to ten years of follow-up (T6). The association between CRF
and psychological distress persistence was also evaluated.
To the evaluation which utilizes the cut-off of 36, a qualitative
analysis was added to assess the change in CRF patterns according
to the clinically significant difference (SCIDs) in changes over time
within every single patient. Cella has identified the deviation of
three points in the FACT questionnaire as equivalent of a clinically
significant change in CRF [40]. According to SCIDs, the direction of
change has been classified in “improvement”, “worsening” and
“stable” classes: “improvement” involves an increase in CRF scores
of at least three points, “worsening” a decrease of at least three
points, “stable” a decrease or an increase of less than three points.
Formal tests, such as the EORTC QLQ, may fail to adequately
capture the CRF patient experience. For this reason, the study has
utilized a structured interview carried out for a QoL assessment
project in different early cancers. The interview evaluated the pa-
tient perception of treatments sequelae that most impacted his
quality of life. The patient perception of these sequelae, some
common to all disease sites, and others unique, is not included in
the questionnaires but essential in the lives of patients.
For this study, we analyzed only two areas of the structured
interview that were more specific to fatigue in BC: the patient's
perception of CRF as the experience which has the most impact on
daily functioning, during treatment and follow-up; CRF onset and
decline compared to CT infusion time.
A comparison was made between the CRF patient's subjective
perception, taken from the interview and the CRF scores stemming
from the FACT-F.
2.1. Statistical analysis
Data on the psychological assessment were summarized using
mean and standard deviations or absolute counts and percentages.
Differences between mean values were evaluated with the Stu-
dent's t-test, paired or not according to the setting. Associations
between patient characteristics and data dichotomized according
to cut-off values were analyzed with the chi-square test. Repeated
measurements analysis of variance (ANOVA) was used to test dif-
ferences in CRF over time. A multiple correspondence analysis
(MCA) was applied to investigate the interrelationships among the
factors considered. This kind of analysis is mainly descriptive and
resumes information on association among factors considered
through a graphical representation. IBM SPSS version. 21 was used
as statistical software.
3. Results
From September 2002 to January 2004, a total of 112 patientswere identified. Patient characteristics are summarized in Table 1.
Included and evaluate patients are shown in Fig. 1. Thirty-four pa-
tients did not meet the inclusion criteria, therefore a total of 78
patients were evaluable for the study. At T2 and T3, the number of
patients who continued the study were 75 (3 patients continued
treatment in other centers) and 71 (4 patients refused to continue
due to too much study burden), respectively. At T4, 65 patients (6
patients refused due to personal problems, medical issues or too
much study burden), and 62 patients at T5 (2 deaths from disease, 1
patient refused to continue the study), and 56 patients at T6 (3
patients had progression disease and 3 lost to follow up).
No differences were observed both in terms of age and meno-
pausal status between patients with prolonged follow-up
compared with patients lost to follow up (56 vs 22). In contrast a
statistically significant differencewas shown in patients underwent
to OT (p ¼ 0.01).
All patients were examined for toxicity. The most common se-
vere toxicities (grade 3 and 4) were leukopenia and neutropenia
reported in 24 (30.7%) and 17 (21.7%) patients, respectively, and 4
(5.1%) patients were affected by neutropenic fever. Severe throm-
bocytopenia was not observed. From the start of treatment, 24
(30.7%) patients were observed to have reduced levels of hemo-
globin of 2 gr/dl (median value of Hgb 14.2 vs 11.8). Severe non
hematological toxicities were uncommon. Alopecia was reported in
the majority of patients (89.7%), moderate nausea and vomiting
were observed in 20 (25.6%) and 17 (21.7%) patients, respectively.
Mild peripheral neurotoxicity was observed in 28 (35.8%) patients.3.1. CRF roller coaster effect
The analysis of the onset and decline of CRF during treatment
Fig. 1. Flow chart of included and evaluated patients on different study time.
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and normalization took place within 7 days prior to the next cycle
in 81% of patients.
3.2. The time course of CRF
Fig. 2 Time course of CRF according to the cut-off value of 36.Fig. 2. CRF peCRFwas detected at baseline in 7/78 (9%) patients, in 38/78 at T1
(49%), in 35/75 at T2 (47%), in 22/71 at T3 (31%), in 8/65 at T4 (12%),
in 2/62 at T5 (3%) and in 3/56 at T6 (5%).
3.3. CRF persistence
Compared to a total of 38 (49%) fatigued patients at T1, the
persistent CRF regarded 25 patients (33%), 15 (21%) and 7 (11%)
patients at T2, T3, T4, respectively (Fig. 3). At T5 and T6 no patient
showed persistent CRF (Fig. 2).
3.4. Qualitative analysis among patients with CRF
Out of 38 fatigued patients at T1, 11 (29%) showed an
improvement with CRF levels above the cut-off rate of 36 (no CRF:
29%), 5 patients improved in terms of SCIDs but continued to have
CRF <36 (13%), 7 patients further worsened (18%) and 13 patients
(34%) showed levels of fatigue steadily below threshold at T2. For 2
patients (5%) data are missing.
At T2 CRF rose in 10 patients consequently the number of pa-
tients with fatigue increased to 35 (47%).
At T3 6 (8.4%) patients showed an improvement with CRF levels
above the cut-off of 36 (no CRF 60%), 1 out of ten patients (10%)
worsened further, and 3(30%) showed levels of fatigue steadily
below threshold.
At T3, the CRF increased in 3 patients, bringing the number of
patients with CRF to 22 (31%). In all three patients the CRF dis-
continues to T4.
At T4, 15 patients showed an improvement with CRF levels
above the cut-off (no CRF 68%), 2 patients (9%) improved but
continued to have CRF < 36, 1(4%) worsened further, while 4rsistence.
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3.5. Comparison between the subjective perception and the FACT-F
scores
According to the CRF patient's subjective perception, at T1 45
(58%) patients referred that CRF was the worst condition impacting
daily functioning, and only 28 (62%) of them had a CRF <36; at T2
32 (43%)but only 23 of these (72%) have CRF < 36. At T3 10 (14%)
patients referred that the CRF is the worst condition, but only 8
(80%) have scores below 36.
3.6. The course of psychological distress
3.6.1. Anxiety
The anxiety mean scores, assessed with HADs, showed a stable
trend up to 24 months after CT (T4) with a mean score of 8.01, and
an improvement in the subsequent times with a mean score of 6.7.
The anxiety assessed according to the severity thresholds
showed that at T0 the percentage of patients with reactive and
pathological anxiety is greater than that of patients with normal
scores (60% vs. 40), which further increased at T1 (64% vs. 36%),
returned permanently to baseline levels from T2 to T4, and
decreased steadily in the follow-up at 5 and 10 years (Table 2).
3.6.2. Depression
The depression mean scores, assessed with HADs, showed a
stable trend until the end of CT (T2) with a mean score of 8.1 and an
improvement to 10 years of follow-up with a mean score of 6.8.
Depression was assessed according to the severity thresholds
and showed that at T0 the percentage of patients with normal
depression is comparable to that of patients with reactive and
pathological depression (47% vs. 53%). At T1, the number of patients
with reactive and pathological depression increases (41% vs. 59%).
At T2, there was a return to baseline levels and a progressive
decrease in the following evaluations (Table 2).
No concomitant medications were reported.
3.7. Psychological distress persistence
3.7.1. Anxiety
To highlight persistent anxiety, the number of patients that
continuously experienced anxiety levels 8 from T0 to T6 was
calculated.
At T0, a total of 47 (60%) patients experienced anxiety, and
among these anxiety persisted in 44 (56%) at T1, in 39 (55%) pa-
tients at T2, in 31 at T3 (44%), in 26 (40%) patients at T4, in 16(26%)
at T5 and in 13(23%) at T6 (Fig. 3).
3.7.2. Depression
To highlight persistent depression, the number of patients that
continuously presented depression levels 8 from T0 to T6 was
calculated.Table 2
The course of psychological distress.
% Anxiety 0e7 % Anxiety 8e10 % Anxiety >10
Baseline 40 46 14
T1 36 49 15
T2 43 43 14
T3 41 45 14
T4 45 38 16
T5 54 35 11
T6 54 38 8At T0, a total of 41 (53%) patients showed depression, and at T1
40 (52%), at T2, T3,T4, T5, T6 depression continued in 34 (48%), 29
(41%), 24 (37%), 13 (21%), 11 (20%) patients respectively (Fig. 3).
3.7.3. Anxiety and depression associated with CRF
At T2, T3, T4 the persistence of anxiety associated with CRF was
observed in 15 (20%), 8 (11%) and 3 (5%) patients, respectively.
At T2, T3, T4 the persistence of depression and CRF was showed
in 11(15%), 7 (10%) and 3 (5%) patients, respectively.
3.8. The course of QoL
As shown in Fig. 4, all variables of QoL highlighted a deteriora-
tion at T1, T2 and T3, regardless of baseline scores, and then
gradually improved until to reaching higher scores than those in
the baseline at follow-up of 5 and 10 years.
3.9. Clinical and psychosocial factors related to CRF
3.9.1. CRF and psychological distress
In patients with CRF levels <36, anxiety and depression scores
varied compared to non-fatigued patients. At T0, 57% (4/7) of pa-
tients with fatigue had anxiety scores 8 in contrast with 60% of
non-fatigued patients (43/71), at T1 74% patients (28/38) vs. 55%
(22/40) (p ¼ 0.01); at T2 66% (23/35) vs. 50% (20/40), at T3 64% (14/
22) versus 57% (28/49), at T4 75% (6/8) vs. 52% (30/57).
At T0, 43% (3/7) of patients with fatigue <36 had depression
scores higher than 8 vs. 53% of non-fatigued patients (38/71), at T1
66% (25/38) vs. 53% (21/40) (p ¼ 0.05), at T2 57% (20/35) vs. 55%
(22/40), at T3 55% (12/22) vs. 45% (22/49), at T4 87% (7/8) vs. 40%
(23/58).
This finding is also confirmed by the MCA showing that at T1 a
clear difference between patients with and without CRF compared
to psychological distress: patients with CRF scores <36 are also
those with anxiety and depression borderline (8e10) and patho-
logical scores (11) Fig. 5.
3.9.2. CRF and QoL
In regards to the relationship between Qol and CRF, higher
baseline CRF levels are associated with lower global Qol (60 vs. 73
p: 0.01), physical (70 vs. 84 p: 0.003) and role functioning (68 vs. 84
p ¼ 0.02). At T1 the impact of CRF affects all Qol areas (p < 0.05),
except for social and cognitive functioning, at T2 affects all Qol
areas (p < 0.05) with the exception of cognitive functioning, at T3 it
affects only social (61 vs 75 p ¼ 0.01), physical (73 vs. 81 p: 0.04)
and role functioning (70 vs 81 p: 0.03). The greatest impact is
observed at T2.
3.9.3. CRF and clinical features
We studied CRF in association with the patients clinical char-
acteristics including: menopausal status, age, drug-including
chemotherapy, toxicity (grade 2-3-4 anemia, neutropenia and
neurotoxicity) and the adjuvant HT following CT.% Depression 0e7 % Depression 8e10 % Depression >10
47 38 15
41 44 15
44 41 15
52 34 14
55 30 15
57 35 8
60 31 9
Fig. 3. Psychological distress persistence.
Fig. 4. The course of Quality of Life.
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and postmenopausal status, respectively. During the time of
treatment, 16 (39%) and 22 (59%) patients in pre and post meno-
pausal status, respectively showed CRF (p ¼ 0.07). At T3, 14 (42%)
postmenopausal patients presented a significantly higher CRF (<36
value) than 8 (21%) pre-menopausal patients (p ¼ 0.05). At T5 and
T6, the two groups of patients presented no differences.
No differences were observed in the other factors investigated.
Only a trend in patients with peripheral neurotoxicity in thecourse of taxane-containing adjuvant CT was observed (p ¼ 0.07).
4. Discussion
Despite growing interest on behalf of the researchers in CRF and
in understanding this phenomenon, little is known about the
course of CRF along the cancer trajectory and about the clinical,
psychological and demographic risk factors, which could predict
CRF development and persistence in survivors.
Fig. 5. Multiple Correspondence Analysis: CRF at time t1 in relations to some patient’ s features at time t0.
A. Fabi et al. / The Breast 34 (2017) 44e5250The few prospective studies on treating fatigue in BC patients
[1,17,21,22,34,47] reported a wide range in the incidence rate of CRF
during the course of the disease mainly due to the heterogeneity of
treatments, the timing of assessment, the tools used and also the
failure to use the full set of criteria identified in the definition of CRF
[48].
Our prospective, longitudinal study, detected the CRF trajectory
from the surgery to ten years of follow-up.
On the basis of the cut-off rate of 36, clinically significant fatigue
levels were identified after surgery (9%). These levels increased
during (49%) and at the end of the treatments (47%), and continued
to persist after 1 year (31%) and declined in the subsequent time up
to ten years of follow-up.
CRF incidence after surgery, according to Andrikowsly et al. [47],
may be motivated by factors related to the tumor and/or by high
levels of physical and psychological stress related to the cancer
diagnosis and to the surgical treatment outcomes.
Compared to other prospective studies, prevalence of CRF in our
sample was higher at the end of adjuvant systemic therapies and
lower in follow-up [34], probably due to cumulative side effects of
the entire chemotherapy, also if not so high grade and incidence of
side effects were observed. We must take into consideration that
the study started about fifteen years ago and the supportive care for
antiemetics prophylaxis, the management of neutropenia preven-
tion were not available and a better definitions of toxicity grading
reported by the oncologists were not so applied. Furthermore pa-
tient reported outcome was not adopted, and all toxicity felt by the
single patient was reported objectively by the physician, with a
possible bias of real side effect due to therapy. In an era in which
supportive care represents a significant end point of cure, it isneeded to assess the CRF patient perception in the global side ef-
fects both in the course of oncological treatment and follow-up.
Increased CRF prevalence during CT could be also attributed to
the use of only a subset of CRF definition criteria [49].
It is interesting to note that the prevalence of fatigue detected
through the FACT-F is lower than that reported by the patient ac-
cording to the subjective perception of the condition that most
impacts the daily functioning over time. As noted in the literature,
FACT-F may underestimate the number of patients with significant
levels of CRF [15].
CRF is a common condition that mostly impacts daily func-
tioning on 58% of patients during CT treatment and 43% of patients
at the end of the CT. It is not surprising that CRF 1 year from CT is
considered to impact only 14% of patients, indicating overcoming
the effect determined by CT.
The design of most studies on CRF in BC patients allowed to
detect CRF levels but not its duration, that has been defined as the
third dimension [20], making it impossible to distinguish between
patients with transitory and persistent CRF.
This is especially relevant in the population of survivors for
identifying high risk patients needing targeted interventions.
In agreement with the results by Goldstein [34], our study found
CRF persists for 12 months or more after the end of CT treatment in
32% of patients.
The study also showed that at the end of CT the persistence of
CRF is associated with persistent anxiety and depression, respec-
tively in 20% and in 15% of patients, at 12months from the end of CT
in 11% and 10%, and at 2 years of follow-up in 5% of patients.
To date, there is little information available on the behavioral
pattern of CRF from treatment until survivorship phase.
A. Fabi et al. / The Breast 34 (2017) 44e52 51The direction of CRF, according to SCIDs, showed at the end of
the CT persistent fatigue in 57% of patients (stability/worsening),
incident fatigue in 29%, and transient fatigue in 29% of women. A
subset of patients (14%) who remain fatigued was also detected
despite their scores in the improving category (score <36). In the
time following, the percentage of transient fatigue increases,
persistent fatigue remains stable and incident fatigue decreases.
This trend seems to indicate the temporal relationship between CRF
and CT period. The cases of incident fatigue are depletedwithin one
year from completing CT and only 3% patients showed fatigue at 5
years from CT.
The presence of CRF in 5% of patients at 10 years from the end of
CT may underline the role played by other factors, such as the onset
of new stressful life events and the comorbidities associated with
aging.
It is interesting to note that the analysis of clinical, psychological
and demographic characteristics of patients with significant fa-
tigue, has detected only the presence of reactive or pathological
anxiety and depression.
This analysis if extended to a larger sample could highlight
specific subgroups of patients, characterized by a constellation of
clinical, demographic and psychosocial variables that define
different risk conditions. This would allow not only to stratify pa-
tients in clinical trials but also to target interventions to improve
CRF and psychological distress according to the risk level.
Our study confirm previous studies [50e52] which underline
the “roller coaster effect” with a significant increase in levels of
fatigue immediately after infusion.
As to the QoL over time, we observed worsening during the end
and at 1 year of CT, and an improvement in the period of time
thereafter. This last observation may possibly reflect the process of
patient adaptation. Various explanations have been given for the
presence of a good quality of life in long-term survivors. One
explanation could be the concept of reframing/shift [53] in
response which we hypothesize that BC survivors either establish a
new meaning of the concept of QoL or change their own internal
standards as a result of adaptation to the limitations associated
with the disease or its treatment. Another reason for a good QoL
could be the finding of any type of benefit arising from the cancer
experience, known as benefit finding or post-traumatic growth
[54]. Anxiety and depression, according to the QoL trend, showed
the presence of a reactive/pathological disorder during and at the
end of CTand at 1 year from the end of adjuvant systemic treatment
and a return to normality scores in the period of time thereafter.
In regards to the relationship between CRF and Qol, several
studies have shown a lower Qol in fatigued patients and the
negative effects of CRF on daily functioning during CT and in BC
survivors [1,27].
It was further highlighted that this relationship could justify the
poor compliance to CT regimens and discontinuation of therapy,
thus underlining the importance of CRF improvement in-
terventions in this category of patients [19,28e30].
According to these studies the most impacted areas in our
sample are those related to the daily functioning (physical and role
functioning).
As far as the relationship between CRF and psychological
distress, our study showed that, since the CRF onset up to 24
months of follow-up, the patients with CRF scores <36 had anxiety
and depression scores higher than the cut-off of 8 in the same
evaluation, indicating a relationship between the presence of CRF
and the presence of psychological distress. Graphics representing
multiple correspondence analysis evidence the significant rela-
tionship between baseline scores of anxiety and depression ¼> 8
(HADS) and CRF scores (FACT-F <36) during adjuvant treatment
and in the following evaluations indicating that women presentingreactive and pathological depression and anxiety before CT treat-
ment are at risk for the onset of fatigue in a later period. Direc-
tionality between CRF and mental state is still difficult to confirm
due to lacking data regarding fatigue before illness as well as our
small sample that prevents carrying out further statistical analysis.
Our study supports those studies that do not detect a relation-
ship between CRF and factors related to the disease and treatment
[6,18,55]. The observed trend between CRF and both post-
menopausal status and peripheral neurotoxicity underline the
impact on fatigue of these two factors (p ¼ 0.07).
The ability to determine the predictors of trajectory of fatigue
during and after CTcould makeway for preventive strategies on the
management of patients who are at greater risk of fatigue.
The strength of our study lies in the prospective and long-term
CRF view, and in its quantitative and qualitative analysis within a
homogeneous sample. The prospective longitudinal design of the
study permits to identify the CRF incidence rate, timing of onset,
duration, and the impact on QoL.
Despite these strengths, the study also has its limitations.
The small of sample size and its reduction over time do not
allow a subgroup analysis. CRF incidence is conditioned by the use
of only some criteria established for adequate definition of CRF,
preventing to be able to obtain a comparison and a clear inter-
pretation of the results. A shared definition of fatigue promotes the
understanding of its etiology and the development of evidence-
based approaches to address it.
Moreover, while the choice of HADS as a psychological distress
evaluation tool showed characteristics of higher specificity than the
FACT-F and less contamination of is relationship with CRF, the
choice of FACT-F recognizes certain limits. According to our opinion,
its use appears to be more appropriate in clinical practice and into
intervention studies rather than in the research. Furthermore, the
choice of a cut-off for discriminating between cases and non-cases
while accounting for CRF severity, does not consider CRF charac-
teristics that bear clinical significance. In addition, the instrument's
low specificity producing a high number of false negatives could
reduce the generalizability of the study results. Thus, a diagnostic
interview is required.
The absence of a CRF assessment before the onset of disease and
the absence of a control group makes it difficult to clearly deter-
mine whether the CRF is linked to diagnosis and treatment for
cancer as well as to identify common and specific predictors of CRF
in cancer survivors and in healthywomen. Several studies however,
found a lower prevalence of fatigue (12e22%) in the general pop-
ulation than in BC women after treatment [21].
Furthermore, although women with certain comorbidities
linked to significant fatigue symptoms were excluded from study,
we did not assess the onset of physical comorbidity over time. Such
comorbidities can affect the experience of fatigue and ideally
should be included as control variables in future analyses
comparing patients with CRF and those without.
Overall, the findings of the current study suggest that the
persistence of fatigue is experienced by a minority of women
treated with chemotherapy followed or not by hormonal therapy
for early BC. The Identification of biological and psychological CRF
targets could be significantly helpful for early interventions in a
subset of patients who are at more risk of developing fatigue.
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